Praxis’ epilepsy drug reduces seizures by 46% in pediatric patients in Phase 2 study

Praxis Precision Medicines released another batch of topline data from its epilepsy program on Tuesday, this time from the Phase 2 EMBOLD study investigating relutrigine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

University of Colorado Denver Unveils Psychedelic Research Center | Psychedelic Invest

The University of Colorado Denver has taken a groundbreaking step with the establishment of the CU Denver Center for Psychedelic Research. This innovative center aims

July 2, 2024

Hearing intervention shows promise in protecting older adults at increased risk for cognitive decline

While the results were negative in the total study population, the hearing intervention slowed cognitive decline in older adults with mild to moderate hearing loss

July 20, 2023

Understanding the impact of tobacco smoking and smoking cessation on life expectancy of HIV patients in South Africa

Krishna Reddy, MD, MS, a physician-investigator at the Medical Practice Evaluation Center and the Tobacco Research and Treatment Center at Massachusetts General Hospital and an

July 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.